EyePoint Pharmaceuticals (EYPT) Stock Analysis

What EyePoint Pharmaceuticals does

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.

Key metrics

ETFs linked to EYPT

Broad-market and Healthcare sector ETFs an investor holding EyePoint Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EYPT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals trades under the ticker EYPT on NASDAQ.

Which exchange is EYPT listed on?

EYPT is listed on NASDAQ.

What sector does EyePoint Pharmaceuticals operate in?

EyePoint Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze EYPT in a portfolio?

PortView shows EYPT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.